E Fund Management Hong Kong Co. Ltd. Has $29,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

E Fund Management Hong Kong Co. Ltd. lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5,700.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58 shares of the company’s stock after acquiring an additional 57 shares during the quarter. E Fund Management Hong Kong Co. Ltd.’s holdings in IDEXX Laboratories were worth $29,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Crewe Advisors LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter worth approximately $26,000. Ridgewood Investments LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $28,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new position in IDEXX Laboratories in the 2nd quarter worth approximately $36,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $451.08 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The firm has a fifty day moving average of $481.87 and a two-hundred day moving average of $488.22. The stock has a market capitalization of $37.25 billion, a price-to-earnings ratio of 43.67, a PEG ratio of 4.03 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the company earned $2.67 EPS. IDEXX Laboratories’s quarterly revenue was up 6.4% on a year-over-year basis. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research report on Wednesday, August 14th. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $574.13.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.